文献速递淋巴瘤

单中心大型边缘区淋巴瘤队列中向高级别淋巴瘤转化的危险因素及其对生存的影响

Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution.
PubMed 文献 · J Clin Oncol · 2018-10-12

该单中心队列纳入1995至2016年453例活检证实的边缘区淋巴瘤(MZL)患者,34例(7.5%)发生活检证实向弥漫大B细胞淋巴瘤的高级别转化(HGT)。初始治疗未达完全缓解(SHR 3.76)、乳酸脱氢酶升高(SHR 2.71)及>4个淋巴结区域(SHR 2.97)是HGT的主要预测因素,HGT患者总生存(OS)更短。

要点

  • 453例MZL中34例(7.5%)发生活检证实的HGT,其中7例(21%)在初诊MZL时即诊断。
  • 初始治疗未达CR(SHR 3.76)、LDH升高(SHR 2.71)、>4个淋巴结区域(SHR 2.97)显著增加HGT风险(P<.02)。
  • HGT患者5年OS率65% vs 86%(P<.001),诊断MZL后12个月内出现HGT者4年OS率43% vs 81%(P<.001)。

核心结论

  • 初始治疗未达完全缓解、乳酸脱氢酶升高及MZL诊断时>4个淋巴结区域是HGT风险增加的主要预测因素,HGT患者OS更短。

研究设计与样本

  • 单中心队列分析,纳入1995至2016年在该院就诊的453例活检证实的边缘区淋巴瘤患者。
  • 采用Kaplan-Meier法、Cox比例风险回归和竞争风险方法分析时间-事件结局。

主要发现

  • 34例(7.5%)发生活检证实的向弥漫大B细胞淋巴瘤HGT,其中7例(21%)在初始MZL诊断时即诊断。
  • 27例新发HGT患者的中位至HGT时间为29个月(范围1.3至135个月)。
  • 淋巴结/脾MZL患者的HGT风险更高(亚分布风险比[SHR] 2.60;P=.023)。
  • 多变量竞争风险分析显示,乳酸脱氢酶升高(SHR 2.71)、>4个淋巴结区域(SHR 2.97)及初始治疗未达完全缓解(SHR 3.76)与HGT风险显著升高相关(P<.02)。
  • 国际预后指数(IPI)、滤泡性淋巴瘤IPI及黏膜相关淋巴组织淋巴瘤IPI仅在单变量分析中为HGT的显著预测因素。

关键数值与推荐

  • HGT患者5年OS率65% vs 无HGT患者86%(P<.001)。
  • MZL诊断后12个月内出现HGT者4年OS率43% vs 在MZL诊断时即出现HGT者联合12个月后出现HGT者81%(P<.001)。
  • 未达CR及较高的IPI、滤泡性淋巴瘤IPI、黏膜相关淋巴组织淋巴瘤IPI评分为无进展生存和OS缩短的主要显著预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Given the paucity of data on higher-grade transformation (HGT) to aggressive lymphoma in patients with marginal zone lymphoma (MZL), we report on a large cohort of patients, identify risk factors, and determine HGT impact on overall survival (OS). METHODS: We analyzed 453 patients with biopsy-proven MZL seen at our institution between 1995 and 2016. Kaplan-Meier, Cox proportional hazards regression, and competing risk methods were used in analyses of time-to-event outcomes. RESULTS: Thirty-four patients (7.5%) had biopsy-proven HGT to diffuse large B-cell lymphoma, including seven (21%) diagnosed at the time of initial MZL diagnosis. Among 27 incident patients, median time to HGT was 29 months (range, 1.3 to 135 months). Higher risk of HGT was observed in those with nodal/splenic MZL (subdistribution hazard ratio [SHR], 2.60; P = .023). On multivariable competing risk analysis, elevated lactate dehydrogenase (SHR, 2.71), more than four nodal sites (SHR, 2.97), and failure to achieve complete remission (CR) after initial treatment (SHR, 3.76) conveyed significantly higher risk for HGT ( P < .02). International Prognostic Index (IPI), Follicular Lymphoma IPI, and Mucosa-Associated Lymphoid Tissue Lymphoma IPI were only significant predictors of HGT univariably. Patients with HGT had shorter OS (5-year rate, 65% v 86%; P < .001). Patients who presented with HGT within 12 months since MZL diagnosis had shorter OS than those with HGT at MZL diagnosis combined with those with HGT more than 12 months later (4-year rate, 43% v 81%, P < .001). Non-CR and higher scores of IPI, Follicular Lymphoma IPI, and Mucosa-Associated Lymphoid Tissue Lymphoma IPI were the main significant predictors for shorter progression-free survival and OS. CONCLUSION: Failure to achieve CR after initial treatment, elevated lactate dehydrogenase, and more than four nodal sites at the time of MZL diagnosis are the main predictors of increased risk of HGT. Patients with HGT have shorter OS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Alderuccio JP, Zhao W, Desai A, et al. Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. J Clin Oncol. 2018. PMID: 30312133. doi:10.1200/JCO.18.00138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。